Literature DB >> 23706522

Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know.

Axel Heidenreich, David Pfister, Axel Merseburger, Georg Bartsch.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23706522     DOI： 10.1016/j.eururo.2013.05.021

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  19 in total

Review 1.  An update on enzalutamide in the treatment of prostate cancer.

Authors:  Axel S Merseburger; Gabriel P Haas; Christoph-A von Klot
Journal:  Ther Adv Urol       Date:  2015-02

Review 2.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

3.  Prostate cancer: Sequencing AR-targeted agents might be ineffective in mCRPC.

Authors:  Axel Heidenreich; David Pfister
Journal:  Nat Rev Urol       Date:  2015-04-14       Impact factor: 14.432

4.  Tracking and Functional Characterization of Epithelial-Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis.

Authors:  Marcus Ruscetti; Bill Quach; Eman L Dadashian; David J Mulholland; Hong Wu
Journal:  Cancer Res       Date:  2015-05-06       Impact factor: 12.701

5.  A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Authors:  Daniel Joseph Khalaf; Claudia M Avilés; Arun A Azad; Katherine Sunderland; Tilman Todenhöfer; Berhard J Eigl; Daygen Finch; Lyly Le; Andrew Atwell; Bruce Keith; Christian Kollmannsberger; Kim N Chi
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

6.  Is there an anti-androgen withdrawal syndrome for enzalutamide?

Authors:  Christoph A J von Klot; Mario W Kramer; Alena Böker; Thomas R W Herrmann; Inga Peters; Markus A Kuczyk; Uwe Ligges; Jürgen E Gschwend; Margitta Retz; Sebastian C Schmid; Arnulf Stenzl; Christian Schwentner; Tilmann Todenhöfer; Michael Stöckle; Carsten-Henning Ohlmann; Ines Azone; René Mager; Georg Bartsch; Axel Haferkamp; Axel Heidenreich; Charlotte Piper; Axel S Merseburger
Journal:  World J Urol       Date:  2014-04-02       Impact factor: 4.226

7.  Enzalutamide in European and North American men participating in the AFFIRM trial.

Authors:  Axel S Merseburger; Howard I Scher; Joaquim Bellmunt; Kurt Miller; Peter F A Mulders; Arnulf Stenzl; Cora N Sternberg; Karim Fizazi; Mohammad Hirmand; Billy Franks; Gabriel P Haas; Johann de Bono; Ronald de Wit
Journal:  BJU Int       Date:  2014-10-23       Impact factor: 5.588

Review 8.  Targeting Tumors with Small Molecule Peptides.

Authors:  Andrew G Cheetham; Daniel Keith; Pengcheng Zhang; Ran Lin; Hao Su; Honggang Cui
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

9.  The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants.

Authors:  Hong Wang; Zhe Chang; Guo-di Cai; Ping Yang; Jiang-He Chen; Shan-Shu Yang; Yin-Feng Guo; Ming-Yu Wang; Xue-Hua Zheng; Jin-Ping Lei; Pei-Qing Liu; De-Peng Zhao; Jun-Jian Wang
Journal:  Acta Pharmacol Sin       Date:  2021-07-28       Impact factor: 6.150

10.  Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.

Authors:  Petra Popovics; Andrew V Schally; Luca Szalontay; Norman L Block; Ferenc G Rick
Journal:  Oncotarget       Date:  2014-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.